{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:59:29Z","timestamp":1772164769723,"version":"3.50.1"},"reference-count":96,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H05653"],"award-info":[{"award-number":["19H05653"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H05746"],"award-info":[{"award-number":["19H05746"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24H00066"],"award-info":[{"award-number":["24H00066"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K27379"],"award-info":[{"award-number":["23K27379"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K17431"],"award-info":[{"award-number":["23K17431"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24ck0106906"],"award-info":[{"award-number":["24ck0106906"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21zf0127003h0001"],"award-info":[{"award-number":["21zf0127003h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22J12313"],"award-info":[{"award-number":["JP22J12313"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22KJ2691"],"award-info":[{"award-number":["JP22KJ2691"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The molecular basis of therapy resistance in multiple myeloma remains poorly understood. In this study, we performed single-cell RNA sequencing coupled with VDJ-targeted sequencing of highly purified primary multiple myeloma cells from patient bone marrow. This approach uncovered cellular heterogeneity and phenotypic plasticity of multiple myeloma cells across a spectrum of CD138 expression, accompanied by drastic epigenetic alterations. Notably, therapy-resistant subpopulations were identified within a minor fraction of CD138\u2013 multiple myeloma cells, which were shown via CRISPR\/Cas9 screening to be vulnerable to splicing pathway inhibition. Consistently, this fraction of CD138\u2013 multiple myeloma cells showed increased differential splicing associated with overexpression of SR protein family splicing factors. Among these splicing factors, RBM39 was overexpressed in therapy-resistant cells and involved in aberrant splicing. Both genetic and pharmacologic RBM39 inhibition exhibited a significant lethal effect on multiple myeloma cells. Collectively, our findings identify distinct therapy-resistant multiple myeloma subpopulations and highlight targeting the splicing pathway as a promising therapeutic strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Single-cell RNA sequencing coupled with VDJ-targeted profiling identified distinct therapy-resistant subpopulations within the minor CD138\u2013 fraction of multiple myeloma cells. These subpopulations were characterized by increased differential splicing events associated with overexpression of splicing factors from the SR protein family, with CD138\u2212 cells showing selective vulnerability to pharmacologic targeting of the splicing factor RBM39.<\/jats:p>\n                    <jats:p>See related commentary by Maron and Abdel-Wahab, p. 535<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0340","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:01:51Z","timestamp":1756785711000},"page":"602-622","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-3747","authenticated-orcid":false,"given":"Takahiro","family":"Kamiya","sequence":"first","affiliation":[{"name":"1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."},{"name":"2Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7079-4788","authenticated-orcid":false,"given":"Masahiko","family":"Ajiro","sequence":"additional","affiliation":[{"name":"3Division of Cancer RNA Research, National Cancer Center Research Institute, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6991-815X","authenticated-orcid":false,"given":"Motohiko","family":"Oshima","sequence":"additional","affiliation":[{"name":"1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-6115","authenticated-orcid":false,"given":"Shuhei","family":"Koide","sequence":"additional","affiliation":[{"name":"1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2341-2409","authenticated-orcid":false,"given":"Yaeko","family":"Nakajima-Takagi","sequence":"additional","affiliation":[{"name":"1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2136-4562","authenticated-orcid":false,"given":"Kazumasa","family":"Aoyama","sequence":"additional","affiliation":[{"name":"1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9775-0822","authenticated-orcid":false,"given":"Akiho","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7966-291X","authenticated-orcid":false,"given":"Satoshi","family":"Kaito","sequence":"additional","affiliation":[{"name":"1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2091-4948","authenticated-orcid":false,"given":"Naoki","family":"Itokawa","sequence":"additional","affiliation":[{"name":"1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2903-2332","authenticated-orcid":false,"given":"Ryoji","family":"Ito","sequence":"additional","affiliation":[{"name":"4Central Institute for Experimental Medicine and Life Science, Kanagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-4369","authenticated-orcid":false,"given":"Kiyoshi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"5Division of Clinical Genome Research, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0462-8631","authenticated-orcid":false,"given":"Yoichi","family":"Furukawa","sequence":"additional","affiliation":[{"name":"5Division of Clinical Genome Research, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4014-2789","authenticated-orcid":false,"given":"Bahityar","family":"Rahmutulla","sequence":"additional","affiliation":[{"name":"6Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6980-5515","authenticated-orcid":false,"given":"Atsushi","family":"Kaneda","sequence":"additional","affiliation":[{"name":"6Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan."},{"name":"7Health and Disease Omics Center, Chiba University, Chiba, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9177-4760","authenticated-orcid":false,"given":"Takayuki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan."},{"name":"8Division of Hematology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[{"name":"9Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3210-7756","authenticated-orcid":false,"given":"Taku","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-2670","authenticated-orcid":false,"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-4329","authenticated-orcid":false,"given":"Masayuki","family":"Yamashita","sequence":"additional","affiliation":[{"name":"1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."},{"name":"11Division of Experimental Hematology, Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6257-4152","authenticated-orcid":false,"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0664-7281","authenticated-orcid":false,"given":"Akihide","family":"Yoshimi","sequence":"additional","affiliation":[{"name":"3Division of Cancer RNA Research, National Cancer Center Research Institute, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8263-9902","authenticated-orcid":false,"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan."},{"name":"12Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9410-8992","authenticated-orcid":false,"given":"Atsushi","family":"Iwama","sequence":"additional","affiliation":[{"name":"1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."},{"name":"13Laboratory of Cellular and Molecular Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2025110303132056400_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"2025110303132056400_bib2","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"key":"2025110303132056400_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"2025110303132056400_bib4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"2025110303132056400_bib5","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood.2023020284","article-title":"Potential future direction of measurable residual disease evaluation in multiple myeloma","volume":"142","author":"Mohty","year":"2023","journal-title":"Blood"},{"key":"2025110303132056400_bib6","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025110303132056400_bib7","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","article-title":"Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"2025110303132056400_bib8","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025110303132056400_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025110303132056400_bib10","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"2025110303132056400_bib11","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025110303132056400_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"2025110303132056400_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"key":"2025110303132056400_bib14","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"2025110303132056400_bib15","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"key":"2025110303132056400_bib16","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2023022540","article-title":"ctDNA improves prognostic prediction for patients with relapsed\/refractory MM receiving ixazomib, lenalidomide, and dexamethasone","volume":"143","author":"Kogure","year":"2024","journal-title":"Blood"},{"key":"2025110303132056400_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"2025110303132056400_bib18","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood.2023019758","article-title":"Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis","volume":"142","author":"Poos","year":"2023","journal-title":"Blood"},{"key":"2025110303132056400_bib19","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"2025110303132056400_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"key":"2025110303132056400_bib21","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/leu.2012.80","article-title":"CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients","volume":"26","author":"Hosen","year":"2012","journal-title":"Leukemia"},{"key":"2025110303132056400_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","article-title":"Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma","volume":"121","author":"Chaidos","year":"2013","journal-title":"Blood"},{"key":"2025110303132056400_bib23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3389\/fonc.2018.00566","article-title":"The epigenome in multiple myeloma: impact on tumor cell plasticity and drug response","volume":"8","author":"De Smedt","year":"2018","journal-title":"Front Oncol"},{"key":"2025110303132056400_bib24","first-page":"313","article-title":"Single-cell profiling in multiple myeloma: insights, problems, and promises","volume":"142","author":"Samur","year":"2023","journal-title":"Blood"},{"key":"2025110303132056400_bib25","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"key":"2025110303132056400_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","article-title":"Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing","volume":"27","author":"Cohen","year":"2021","journal-title":"Nat Med"},{"key":"2025110303132056400_bib27","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"key":"2025110303132056400_bib28","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","article-title":"Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease","volume":"41","author":"Dang","year":"2023","journal-title":"Cancer Cell"},{"key":"2025110303132056400_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","article-title":"Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage","volume":"20","author":"Aran","year":"2019","journal-title":"Nat Immunol"},{"key":"2025110303132056400_bib30","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1093\/nar\/gkac781","article-title":"Integrated analysis of multimodal single-cell data with structural similarity","volume":"50","author":"Cao","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2025110303132056400_bib31","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Wuill\u00e8me-Toumi","year":"2005","journal-title":"Leukemia"},{"key":"2025110303132056400_bib32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.14882","article-title":"Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma","volume":"179","author":"Handa","year":"2017","journal-title":"Br J Haematol"},{"key":"2025110303132056400_bib33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3324\/haematol.2022.281167","article-title":"Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins","volume":"108","author":"Taiana","year":"2023","journal-title":"Haematologica"},{"key":"2025110303132056400_bib34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol"},{"key":"2025110303132056400_bib35","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"2025110303132056400_bib36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nature12311","article-title":"A compendium of RNA-binding motifs for decoding gene regulation","volume":"499","author":"Ray","year":"2013","journal-title":"Nature"},{"key":"2025110303132056400_bib37","doi-asserted-by":"crossref","first-page":"e1006384","DOI":"10.1371\/journal.pgen.1006384","article-title":"Wild-type U2AF1 antagonizes the splicing program characteristic of U2AF1-mutant tumors and is required for cell survival","volume":"12","author":"Fei","year":"2016","journal-title":"PLoS Genet"},{"key":"2025110303132056400_bib38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nm.4097","article-title":"Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"key":"2025110303132056400_bib39","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nm.4165","article-title":"Therapeutic targeting of splicing in cancer","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"key":"2025110303132056400_bib40","doi-asserted-by":"crossref","first-page":"14060","DOI":"10.1038\/ncomms14060","article-title":"Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome","volume":"8","author":"Shirai","year":"2017","journal-title":"Nat Commun"},{"key":"2025110303132056400_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41408-022-00759-6","article-title":"In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors","volume":"12","author":"Aktas Samur","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025110303132056400_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-023-00783-0","article-title":"Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway","volume":"13","author":"Liu","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025110303132056400_bib43","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41416-022-02124-7","article-title":"Dysregulation of alternative splicing contributes to multiple myeloma pathogenesis","volume":"128","author":"Song","year":"2023","journal-title":"Br J Cancer"},{"key":"2025110303132056400_bib44","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1002\/ctm2.684","article-title":"Splicing factor arginine\/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication","volume":"12","author":"Zhang","year":"2022","journal-title":"Clin Transl Med"},{"key":"2025110303132056400_bib45","doi-asserted-by":"crossref","first-page":"9998927","DOI":"10.1155\/2023\/9998927","article-title":"Increased expression of SRSF1 predicts poor prognosis in multiple myeloma","volume":"2023","author":"Zhang","year":"2023","journal-title":"J Oncol"},{"key":"2025110303132056400_bib46","doi-asserted-by":"crossref","first-page":"17325","DOI":"10.1074\/jbc.M114.558825","article-title":"Cancer-relevant splicing factor CAPER\u03b1 engages the essential splicing factor SF3b155 in a specific ternary complex","volume":"289","author":"Loerch","year":"2014","journal-title":"J Biol Chem"},{"key":"2025110303132056400_bib47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1107\/S2059798316001248","article-title":"UHM-ULM interactions in the RBM39-U2AF65 splicing-factor complex","volume":"72","author":"Stepanyuk","year":"2016","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"2025110303132056400_bib48","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1016\/j.molcel.2023.11.012","article-title":"RBM39: a druggable metabolic sensor linking RNA splicing, transcriptional regulation, and metabolic reprogramming in cancer","volume":"83","author":"Keun","year":"2023","journal-title":"Mol Cell"},{"key":"2025110303132056400_bib49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-binding protein network in acute myeloid leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Cancer Cell"},{"key":"2025110303132056400_bib50","doi-asserted-by":"crossref","first-page":"eaal3755","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"2025110303132056400_bib51","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat Chem Biol"},{"key":"2025110303132056400_bib52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10637-016-0344-9","article-title":"A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of \u03b12 integrin inhibitor E7820 in patients with advanced solid tumors","volume":"34","author":"Milojkovic Kerklaan","year":"2016","journal-title":"Invest New Drugs"},{"key":"2025110303132056400_bib53","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/cncr.31398","article-title":"Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer"},{"key":"2025110303132056400_bib54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nchembio.1986","article-title":"Correlating chemical sensitivity and basal gene expression reveals mechanism of action","volume":"12","author":"Rees","year":"2016","journal-title":"Nat Chem Biol"},{"key":"2025110303132056400_bib55","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41467-022-28907-3","article-title":"Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma","volume":"13","author":"Nijhuis","year":"2022","journal-title":"Nat Commun"},{"key":"2025110303132056400_bib56","doi-asserted-by":"crossref","first-page":"903016","DOI":"10.3389\/fonc.2022.903016","article-title":"Present and future perspective on PLK1 inhibition in cancer treatment","volume":"12","author":"Chiappa","year":"2022","journal-title":"Front Oncol"},{"key":"2025110303132056400_bib57","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/ijms25010588","article-title":"Replication protein A, the main eukaryotic single-stranded DNA binding protein, a focal point in cellular DNA metabolism","volume":"25","author":"Nasheuer","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"2025110303132056400_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/em.22593","article-title":"Mouse models to explore the biological and organismic role of DNA polymerase beta","volume":"65","author":"Sobol","year":"2024","journal-title":"Environ Mol Mutagen"},{"key":"2025110303132056400_bib59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.18632\/oncotarget.109","article-title":"A critical role for the NFkB pathway in multiple myeloma","volume":"1","author":"Demchenko","year":"2010","journal-title":"Oncotarget"},{"key":"2025110303132056400_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","article-title":"HIF-1\u03b1 signaling: essential roles in tumorigenesis and implications in targeted therapies","volume":"11","author":"Zhao","year":"2024","journal-title":"Genes Dis"},{"key":"2025110303132056400_bib61","doi-asserted-by":"crossref","first-page":"1059715","DOI":"10.3389\/fcell.2022.1059715","article-title":"Targeting TGF-beta signaling in the multiple myeloma microenvironment: steering CARs and T cells in the right direction","volume":"10","author":"Rana","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2025110303132056400_bib62","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/cancers14020353","article-title":"CDK5RAP3, a new BRCA2 partner that regulates DNA repair, is associated with breast cancer survival","volume":"14","author":"Minguill\u00f3n","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025110303132056400_bib63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41417-022-00515-9","article-title":"CDK5RAP3 acts as a tumour suppressor in gastric cancer through the infiltration and polarization of tumour-associated macrophages","volume":"30","author":"Wang","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"2025110303132056400_bib64","doi-asserted-by":"crossref","first-page":"1332626","DOI":"10.3389\/fimmu.2023.1332626","article-title":"An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"2025110303132056400_bib65","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/bloodadvances.2019000122","article-title":"Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression","volume":"4","author":"Walker","year":"2020","journal-title":"Blood Adv"},{"key":"2025110303132056400_bib66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"key":"2025110303132056400_bib67","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1002\/stem.2199","article-title":"Myeloma propagating cells, drug resistance and relapse","volume":"33","author":"Karadimitris","year":"2015","journal-title":"Stem Cells"},{"key":"2025110303132056400_bib68","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2025110303132056400_bib69","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"2025110303132056400_bib70","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nsmb1209","article-title":"The gene encoding the splicing factor SF2\/ASF is a proto-oncogene","volume":"14","author":"Karni","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"2025110303132056400_bib71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nsmb.2756","article-title":"Splicing factor SRSF6 promotes hyperplasia of sensitized skin","volume":"21","author":"Jensen","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"2025110303132056400_bib72","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/nar\/gkv1500","article-title":"A genome landscape of SRSF3-regulated splicing events and gene expression in human osteosarcoma U2OS cells","volume":"44","author":"Ajiro","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2025110303132056400_bib73","doi-asserted-by":"crossref","first-page":"111704","DOI":"10.1016\/j.celrep.2022.111704","article-title":"MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors","volume":"41","author":"Urbanski","year":"2022","journal-title":"Cell Rep"},{"key":"2025110303132056400_bib74","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1083\/jcb.200710051","article-title":"Spatial mapping of splicing factor complexes involved in exon and intron definition","volume":"181","author":"Ellis","year":"2008","journal-title":"J Cell Biol"},{"key":"2025110303132056400_bib75","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bbagrm.2009.06.002","article-title":"Interactome for auxiliary splicing factor U2AF(65) suggests diverse roles","volume":"1789","author":"Prigge","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"2025110303132056400_bib76","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbagrm.2016.06.007","article-title":"Global regulation of alternative RNA splicing by the SR-rich protein RBM39","volume":"1859","author":"Mai","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"2025110303132056400_bib77","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1038\/s41467-023-40254-5","article-title":"Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39","volume":"14","author":"Campagne","year":"2023","journal-title":"Nat Commun"},{"key":"2025110303132056400_bib78","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.bjc.6603606","article-title":"A phase I and pharmacokinetic study of indisulam in combination with carboplatin","volume":"96","author":"Dittrich","year":"2007","journal-title":"Br J Cancer"},{"key":"2025110303132056400_bib79","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-06-0249","article-title":"A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer","volume":"13","author":"Talbot","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2025110303132056400_bib80","doi-asserted-by":"crossref","first-page":"e1005116","DOI":"10.1371\/journal.pgen.1005116","article-title":"CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-\u03b1-Gabpa and stress-induced adaptive responses via NF-\u03baB-cMYC","volume":"11","author":"Kang","year":"2015","journal-title":"PLoS Genet"},{"key":"2025110303132056400_bib81","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/biomedicines6020059","article-title":"The NF-\u03baB activating pathways in multiple myeloma","volume":"6","author":"Roy","year":"2018","journal-title":"Biomedicines"},{"key":"2025110303132056400_bib82","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025110303132056400_bib83","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","article-title":"Dual inhibition of EZH2 and EZH1 sensitizes PRC2-dependent tumors to proteasome inhibition","volume":"23","author":"Rizq","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025110303132056400_bib84","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12185-019-02615-z","article-title":"Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry","volume":"109","author":"Takamatsu","year":"2019","journal-title":"Int J Hematol"},{"key":"2025110303132056400_bib85","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"2025110303132056400_bib86","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/bioinformatics\/btaa751","article-title":"Systematic determination of the mitochondrial proportion in human and mice tissues for single-cell RNA-sequencing data quality control","volume":"37","author":"Osorio","year":"2021","journal-title":"Bioinformatics"},{"key":"2025110303132056400_bib87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13059-025-03559-w","article-title":"Filtering cells with high mitochondrial content depletes viable metabolically altered malignant cell populations in cancer single-cell studies","volume":"26","author":"Yates","year":"2025","journal-title":"Genome Biol"},{"key":"2025110303132056400_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-025-01006-0","article-title":"SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors","author":"Lightbody","year":"2025","journal-title":"Nat Cancer"},{"key":"2025110303132056400_bib89","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41467-024-55308-5","article-title":"Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial","volume":"16","author":"Nadeem","year":"2025","journal-title":"Nat Commun"},{"key":"2025110303132056400_bib90","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/1471-2164-14-632","article-title":"An expression atlas of human primary cells: inference of gene function from coexpression networks","volume":"14","author":"Mabbott","year":"2013","journal-title":"BMC Genomics"},{"key":"2025110303132056400_bib91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2025110303132056400_bib92","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1093\/bioinformatics\/btz438","article-title":"PSI-sigma: a comprehensive splicing-detection method for short-read and long-read RNA-seq analysis","volume":"35","author":"Lin","year":"2019","journal-title":"Bioinformatics"},{"key":"2025110303132056400_bib93","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1101\/gr.227181.117","article-title":"A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma","volume":"28","author":"Lin","year":"2018","journal-title":"Genome Res"},{"key":"2025110303132056400_bib94","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-019-1618-0","article-title":"Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis","volume":"574","author":"Yoshimi","year":"2019","journal-title":"Nature"},{"key":"2025110303132056400_bib95","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/bioinformatics\/btab203","article-title":"STREME: accurate and versatile sequence motif discovery","volume":"37","author":"Bailey","year":"2021","journal-title":"Bioinformatics"},{"key":"2025110303132056400_bib96","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/gb-2007-8-2-r24","article-title":"Quantifying similarity between motifs","volume":"8","author":"Gupta","year":"2007","journal-title":"Genome Biol"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0340\/3647417\/bcd-24-0340.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0340\/3658892\/bcd-24-0340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/602\/3663433\/bcd-24-0340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/602\/3663433\/bcd-24-0340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:13:39Z","timestamp":1762157619000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/6\/602\/766820\/Identification-of-a-CD138-Negative-Therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":96,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,29]]},"published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0340","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.30516169","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516166","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8125960","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}